MicroDose’s business model is two-fold: 

1. To create improved partnered products by combining our proprietary drug delivery technologies with pharmaceutical and biotechnology company compounds, and  
   
   
2. to develop, for its own purposes, pharmaceutical products utilizing its proprietary drug delivery technologies with generic compounds, for late stage partnering, co-marketing or sale.

For partnered products, MicroDose traditionally licenses its technologies on an individual molecule basis, and within geographical limits. In exchange, MicroDose receives license fees, milestone payments and royalties on drug sales, with necessary development costs born by the partner. This strategy enables MicroDose to form multiple strategic partnerships, and is therefore not dependent on any one product or company to achieve commercial success. MicroDose has strategic alliances with world-leading pharmaceutical companies.

By pursuing this business model, MicroDose greatly reduces its need for capital in bringing its products to market, and at the same time reduces risk by diversifying its portfolio across multiple compounds and therapies.

Please visit our User Agreement. Your continued use of this site will automatically constitute your agreement to be bound by all the terms and conditions of the User Agreement.

©2004 MicroDose Technologies, Inc.